Connors Investor Services Inc. decreased its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report) by 3.8% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 34,651 shares of the company’s stock after selling 1,378 shares during the quarter. Connors Investor Services Inc. owned approximately 0.07% of Prestige Consumer Healthcare worth $2,386,000 at the end of the most recent quarter.
Several other hedge funds also recently bought and sold shares of the company. Opal Wealth Advisors LLC purchased a new position in Prestige Consumer Healthcare during the second quarter valued at $26,000. Principal Securities Inc. purchased a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at about $29,000. Quest Partners LLC increased its holdings in shares of Prestige Consumer Healthcare by 2,826.7% in the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after purchasing an additional 424 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in Prestige Consumer Healthcare by 80.6% in the 1st quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock worth $33,000 after acquiring an additional 208 shares during the last quarter. Finally, Gladius Capital Management LP purchased a new stake in Prestige Consumer Healthcare during the second quarter valued at $35,000. Institutional investors own 99.95% of the company’s stock.
Prestige Consumer Healthcare Stock Performance
Prestige Consumer Healthcare stock opened at $73.68 on Tuesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.23 and a quick ratio of 1.90. The firm has a market capitalization of $3.65 billion, a P/E ratio of 17.67, a price-to-earnings-growth ratio of 2.06 and a beta of 0.48. Prestige Consumer Healthcare Inc. has a 1-year low of $56.34 and a 1-year high of $75.80. The company’s 50-day moving average is $70.88 and its 200 day moving average is $69.58.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on PBH shares. Canaccord Genuity Group restated a “buy” rating and issued a $80.00 target price on shares of Prestige Consumer Healthcare in a report on Tuesday, May 21st. DA Davidson raised their price objective on Prestige Consumer Healthcare from $93.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, August 28th. Finally, StockNews.com downgraded Prestige Consumer Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, May 21st. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $98.75.
Read Our Latest Research Report on Prestige Consumer Healthcare
About Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Featured Stories
- Five stocks we like better than Prestige Consumer Healthcare
- How to Invest in Blue Chip Stocks
- Boston Scientific: Why This MedTech Giant Isn’t Slowing Down
- How to Calculate Inflation Rate
- Silver’s Breakout: 3 Momentum Stocks You Can’t Miss
- How to Capture the Benefits of Dividend Increases
- Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.